Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP
- PMID: 35842959
- DOI: 10.1016/j.compbiolchem.2022.107726
Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP
Abstract
PI3K pathway is heavily emphasized in cancer where PIK3CA, which encodes for the p110α subunit of PI3Kα, presents itself as the second most common mutated gene. A lot of effort has been put in developing PI3K inhibitors, opening promising avenues for the treatment of cancer. Among these, PI3Kα specific inhibitor alpelisib was approved by FDA for breast cancer and other α-isoform specific inhibitors such as inavolisib and serabelisib reached clinical trials. However, the mode of action of these inhibitors on mutated PI3Kα and how they interact with mutant structures has not been fully elucidated yet. In this study, we are revealing the calculated interactions and binding affinities of these inhibitors within the context of PIK3CA hotspot mutations (E542K, E545K and H1047R) by employing molecular dynamics (MD) simulations. We performed principal component analysis to understand the motions of the protein complex during our simulations and also checked the correlated motions of all amino acids. Binding affinity calculations with MM-PBSA confirmed the consistent binding of alpelisib across mutations and revealed relatively higher affinities for inavolisib towards wild-type and H1047R mutant structures in comparison to other inhibitors. On the other hand, E542K mutation significantly impaired the interaction of inavolisib and serabelisib with PI3Kα. We also investigated the structural relationship of the natural ligand ATP with PI3Kα, and interestingly realized a significant reduction in binding affinity for the mutants, with potentially unexpected implications on the mechanisms that render these mutations oncogenic. Moreover, correlated motions of all residues were generally higher for ATP except the H1047R mutation which exhibited a distinguishable reduction. The results presented here could be guiding for pre-clinical and clinical studies of personalized medicine where individual mutations are a strong consideration point.
Keywords: ATP; Alpelisib; E542K; E545K; H1047R; Inavolisib; Molecular dynamics; PI3K; PIK3CA; Serabelisib.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Similar articles
-
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.Invest New Drugs. 2014 Dec;32(6):1134-43. doi: 10.1007/s10637-014-0152-z. Epub 2014 Aug 26. Invest New Drugs. 2014. PMID: 25152245
-
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.Cancer Discov. 2024 Feb 8;14(2):227-239. doi: 10.1158/2159-8290.CD-23-0704. Cancer Discov. 2024. PMID: 37916958 Free PMC article.
-
ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding.Biochem J. 2024 Dec 4;481(23):1787-1802. doi: 10.1042/BCJ20240479. Biochem J. 2024. PMID: 39485310 Free PMC article.
-
The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Adv Biol Regul. 2023 Jan;87:100934. doi: 10.1016/j.jbior.2022.100934. Epub 2022 Nov 15. Adv Biol Regul. 2023. PMID: 36402737 Free PMC article. Review.
-
Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.Annu Rev Pharmacol Toxicol. 2025 Aug 19. doi: 10.1146/annurev-pharmtox-082924-022724. Online ahead of print. Annu Rev Pharmacol Toxicol. 2025. PMID: 40829787 Review.
Cited by
-
Designing Novel Aspartic Protease (NAP) Using Ancestral Sequence Reconstruction (ASR) for Cheesemaking.Mol Biotechnol. 2025 Jul 7. doi: 10.1007/s12033-025-01470-0. Online ahead of print. Mol Biotechnol. 2025. PMID: 40622661
-
Structure-based cheminformatics and molecular dynamics profiling of potential SIRT6 inhibitors.Mol Divers. 2025 Jul 12. doi: 10.1007/s11030-025-11285-5. Online ahead of print. Mol Divers. 2025. PMID: 40650732
-
A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors.Mol Divers. 2024 Aug;28(4):1907-1924. doi: 10.1007/s11030-023-10799-0. Epub 2024 Feb 2. Mol Divers. 2024. PMID: 38305819
-
New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective.Cancers (Basel). 2024 Dec 24;17(1):16. doi: 10.3390/cancers17010016. Cancers (Basel). 2024. PMID: 39796647 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous